Cargando…

Mucin Glycans: A Target for Cancer Therapy

Mucin glycans are an important component of the mucus barrier and a vital defence against physical and chemical damage as well as pathogens. There are 20 mucins in the human body, which can be classified into secreted mucins and transmembrane mucins according to their distributions. The major differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lingbo, Zhang, Yuhan, Li, Wenyan, Zhang, Jing, Zhang, Yuecheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609567/
https://www.ncbi.nlm.nih.gov/pubmed/37894512
http://dx.doi.org/10.3390/molecules28207033
_version_ 1785128043702910976
author Sun, Lingbo
Zhang, Yuhan
Li, Wenyan
Zhang, Jing
Zhang, Yuecheng
author_facet Sun, Lingbo
Zhang, Yuhan
Li, Wenyan
Zhang, Jing
Zhang, Yuecheng
author_sort Sun, Lingbo
collection PubMed
description Mucin glycans are an important component of the mucus barrier and a vital defence against physical and chemical damage as well as pathogens. There are 20 mucins in the human body, which can be classified into secreted mucins and transmembrane mucins according to their distributions. The major difference between them is that secreted mucins do not have transmembrane structural domains, and the expression of each mucin is organ and cell-specific. Under physiological conditions, mucin glycans are involved in the composition of the mucus barrier and thus protect the body from infection and injury. However, abnormal expression of mucin glycans can lead to the occurrence of diseases, especially cancer, through various mechanisms. Therefore, targeting mucin glycans for the diagnosis and treatment of cancer has always been a promising research direction. Here, we first summarize the main types of glycosylation (O-GalNAc glycosylation and N-glycosylation) on mucins and the mechanisms by which abnormal mucin glycans occur. Next, how abnormal mucin glycans contribute to cancer development is described. Finally, we summarize MUC1-based antibodies, vaccines, radio-pharmaceuticals, and CAR-T therapies using the best characterized MUC1 as an example. In this section, we specifically elaborate on the recent new cancer therapy CAR-M, which may bring new hope to cancer patients.
format Online
Article
Text
id pubmed-10609567
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106095672023-10-28 Mucin Glycans: A Target for Cancer Therapy Sun, Lingbo Zhang, Yuhan Li, Wenyan Zhang, Jing Zhang, Yuecheng Molecules Review Mucin glycans are an important component of the mucus barrier and a vital defence against physical and chemical damage as well as pathogens. There are 20 mucins in the human body, which can be classified into secreted mucins and transmembrane mucins according to their distributions. The major difference between them is that secreted mucins do not have transmembrane structural domains, and the expression of each mucin is organ and cell-specific. Under physiological conditions, mucin glycans are involved in the composition of the mucus barrier and thus protect the body from infection and injury. However, abnormal expression of mucin glycans can lead to the occurrence of diseases, especially cancer, through various mechanisms. Therefore, targeting mucin glycans for the diagnosis and treatment of cancer has always been a promising research direction. Here, we first summarize the main types of glycosylation (O-GalNAc glycosylation and N-glycosylation) on mucins and the mechanisms by which abnormal mucin glycans occur. Next, how abnormal mucin glycans contribute to cancer development is described. Finally, we summarize MUC1-based antibodies, vaccines, radio-pharmaceuticals, and CAR-T therapies using the best characterized MUC1 as an example. In this section, we specifically elaborate on the recent new cancer therapy CAR-M, which may bring new hope to cancer patients. MDPI 2023-10-11 /pmc/articles/PMC10609567/ /pubmed/37894512 http://dx.doi.org/10.3390/molecules28207033 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sun, Lingbo
Zhang, Yuhan
Li, Wenyan
Zhang, Jing
Zhang, Yuecheng
Mucin Glycans: A Target for Cancer Therapy
title Mucin Glycans: A Target for Cancer Therapy
title_full Mucin Glycans: A Target for Cancer Therapy
title_fullStr Mucin Glycans: A Target for Cancer Therapy
title_full_unstemmed Mucin Glycans: A Target for Cancer Therapy
title_short Mucin Glycans: A Target for Cancer Therapy
title_sort mucin glycans: a target for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609567/
https://www.ncbi.nlm.nih.gov/pubmed/37894512
http://dx.doi.org/10.3390/molecules28207033
work_keys_str_mv AT sunlingbo mucinglycansatargetforcancertherapy
AT zhangyuhan mucinglycansatargetforcancertherapy
AT liwenyan mucinglycansatargetforcancertherapy
AT zhangjing mucinglycansatargetforcancertherapy
AT zhangyuecheng mucinglycansatargetforcancertherapy